Functional Constipation Market to Accelerate Substantially During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Takeda, Allergan, Takeda, Renexxion, Gelesis, Synergy Pharmaceuticals

 Breaking News
  • No posts were found

Functional Constipation Market to Accelerate Substantially During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Takeda, Allergan, Takeda, Renexxion, Gelesis, Synergy Pharmaceuticals

Functional Constipation Market to Accelerate Substantially During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Takeda, Allergan, Takeda, Renexxion, Gelesis, Synergy Pharmaceuticals
Delveinsight Business Research LLP
As per DelveInsight, the Functional Constipation Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population, technological advancements, and the launch of upcoming therapies in the market.

DelveInsight’s “Functional Constipation Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Functional Constipation market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Functional Constipation drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Functional Constipation treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Functional Constipation Market

Functional Constipation: An Overview

Functional Constipation (FC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. Functional Constipation is also referred to as chronic idiopathic constipation (CIC), as Functional Constipation is classified as one of the functional gastrointestinal disorders (FGDs). It is estimated that approximately 14% of the population experiences chronic constipation. Possible Functional Constipation causes could be a reduction in fluid and fiber intake in the diet, changes in water balance, and changes in contractility of the colon.

Functional Constipation is characterized by infrequent stools which are often difficult to pass. It typically affects women and older adults. The typical symptom of this condition is passing fewer than three bowel movements per week for more than six months.

Functional Constipation Market Key Facts

  • As per ADA Health, eight million people in the US seek medical care for constipation every year, and one million are hospitalized. It is likely that many people who have Functional Constipation do not report the condition to their doctors because they are embarrassed or do not see it as a major problem requiring medical care.

  • As per a 2011 study conducted by Suares et al., out of the 100 papers evaluated, 45 reported the prevalence of Functional Constipation in 41 separate study populations, containing 261,040 subjects with a pooled prevalence of Functional Constipation in all studies was 14%. They also found that the prevalence of Functional Constipation was higher in women and increased with age and lower socioeconomic status.

  • According to the 2018 study conducted by Black et al., the prevalence of Functional Constipation increases with age, with higher rates reported in older people.

Functional Constipation Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Functional Constipation pipeline therapies. It also thoroughly assesses the Functional Constipation market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Functional Constipation drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Functional Constipation Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Functional Constipation epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Functional Constipation epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Functional Constipation Epidemiology, Segmented as –

  • Prevalent Population of Functional Constipation (FC) (2019–2032)

  • Age-specific Prevalent Population of Functional Constipation (FC) (2019–2032)

  • Gender-specific Prevalent Population of Functional Constipation (FC) (2019–2032)

  • Diagnosed and Treatable Cases of Functional Constipation (FC) (2019–2032)

Functional Constipation Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Functional Constipation market or expected to be launched during the study period. The analysis covers the Functional Constipation market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Functional Constipation drugs based on their sale and market share.

The report also covers the Functional Constipation pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Functional Constipation companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Functional Constipation Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/functional-constipation-market

Functional Constipation Therapeutics Analysis

The treatment options for Functional Constipation include Dietary Fiber, Laxatives, and Medications. The major difficulty faced by patients suffering from Functional Constipation is a lack of proper digestion, which results in the hardening of the stools. It is advised to intake large amounts of water to soften the stools along with modifications in the diet, which is rich in fiber so that there is an improvement in digestion. Stool softeners are used to avoid straining when the patient has a movement, like after surgery. They are best for short-term use. They work by pulling in water from your intestines to soften your stool. Docusate (Colace, DulcoEase, Surfak) is a commonly used stool softener.

Additionally, there are several FDA-approved drugs available to treat Functional Constipation, which include Motegrity (Prucalopride), Linzess (linaclotide), and Trulance (plecanatide) by Takeda, Allergan, and Synergy Pharmaceuticals, respectively. To further improve the treatment scenario, several major pharma and biotech companies are actively working in the Functional Constipation therapeutics market.

Functional Constipation Companies Actively Working in the Therapeutics Market Include

  • Takeda

  • Allergan

  • Synergy Pharmaceuticals

  • Takeda Pharmaceuticals

  • Renexxion

  • Gelesis

And Many Others

Emerging and Marketed Functional Constipation Therapies Covered in the Report Include:

  • Motegrity: Takeda

  • Linzess: Allergan

  • Trulance: Synergy Pharmaceuticals

  • Amitiza: Takeda Pharmaceuticals

  • Naronapride: Renexxion

  • GS500: Gelesis

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/functional-constipation-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Functional Constipation Competitive Intelligence Analysis

4. Functional Constipation Market Overview at a Glance

5. Functional Constipation Disease Background and Overview

6. Functional Constipation Patient Journey

7. Functional Constipation Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Functional Constipation Treatment Algorithm, Current Treatment, and Medical Practices

9. Functional Constipation Unmet Needs

10. Key Endpoints of Functional Constipation Treatment

11. Functional Constipation Marketed Therapies

12. Functional Constipation Emerging Drugs and Latest Therapeutic Advances

13. Functional Constipation Seven Major Market Analysis

14. Attribute Analysis

15. Functional Constipation Market Outlook (In US, EU5, and Japan)

16. Functional Constipation Companies Active in the Market

17. Functional Constipation Access and Reimbursement Overview

18. KOL Views on the Functional Constipation Market

19. Functional Constipation Market Drivers

20. Functional Constipation Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/functional-constipation-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Negative Pressure Wound Therapy Systems Market

The global Negative Pressure Wound Therapy Systems (NPWT) Market was valued at USD 3.35 billion in 2022, and growing at a CAGR of 5.09% during the forecast period (2023-2028); it is expected to reach USD 4.50 billion by 2028. Some of the key factors such as the rising incidence of chronic wounds associated with various chronic disorders (diabetes, ulcers, and obesity), the rising incidence of active wounds (comprising burns and surgical wounds), an increase in the aging population, rising awareness of proper wound care management, growing funding for wound care research, and technological advancements in wound care product offerings are expected to drive the Negative Pressure Wound Therapy Systems Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories